Given these findings and our previous work highlighting a crucial contribution for cancer cell-intrinsic COX-2/PGE2 activity to immune escape, we next evaluated whether pharmacological inhibition of COX-2 would alter the efficacy of chemoimmunotherapy combinations. Here, PTGS2 is linked to cancer.